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ABSTRACT
Objective The aetiology of Crohn's disease (CD) has
been related to nucleotide-binding oligomerisation
domain containing 2 (NOD2) and ATG16L1 gene
variants. The observation of bacterial DNA translocation
in patients with CD led us to hypothesise that this
process may be facilitated in patients with NOD2/
ATG16L1-variant genotypes, affecting the efﬁcacy of
anti-tumour necrosis factor (TNF) therapies.
Design 179 patients with Crohn's disease were
included. CD-related NOD2 and ATG16L1 variants were
genotyped. Phagocytic and bactericidal activities were
evaluated in blood neutrophils. Bacterial DNA, TNFα,
IFNγ, IL-12p40, free serum inﬂiximab/adalimumab levels
and antidrug antibodies were measured.
Results Bacterial DNA was found in 44% of patients
with active disease versus 23% of patients with remitting
disease (p=0.01). A NOD2-variant or ATG16L1-variant
genotype was associated with bacterial DNA presence (OR
4.8; 95% CI 1.1 to 13.2; p=0.001; and OR 2.4; 95% CI
1.4 to 4.7; p=0.01, respectively). This OR was 12.6 (95%
CI 4.2 to 37.8; p=0.001) for patients with a double-
variant genotype. Bacterial DNA was associated with
disease activity (OR 2.6; 95% CI 1.3 to 5.4; p=0.005).
Single and double-gene variants were not associated with
disease activity (p=0.19). Patients with a NOD2-variant
genotype showed decreased phagocytic and bactericidal
activities in blood neutrophils, increased TNFα levels in
response to bacterial DNA and decreased trough levels of
free anti-TNFα. The proportion of patients on an
intensiﬁed biological therapy was signiﬁcantly higher in the
NOD2-variant groups.
Conclusions Our results characterise a subgroup of
patients with CD who may require a more aggressive
therapy to reduce the extent of inﬂammation and the risk
of relapse.
INTRODUCTION
Understanding the pathogenesis of Crohn’s disease
(CD), one of two major forms of inﬂammatory
bowel disease affecting the population world-
wide,1 2 has experienced enormous progress in
recent years. The aetiology of the disease is par-
tially explained by a disturbance of the interaction
between the host and intestinal microorganisms.3–6
Accordingly, the gut epithelial barrier plays a
crucial role in regulating the uptake of luminal
Signiﬁcance of this study
What is already known about this subject?
▸ Genetic susceptibility and the immunological
interaction between the host and commensal
ﬂora are implicated in the aetiology of Crohn’s
disease (CD).
▸ Gut bacterial DNA translocation into blood is a
frequent event in patients with CD.
▸ Relapse occurs during the course of the disease
in patients with CD, even on
immunosuppressive and/or biological
maintenance treatments.
▸ The efﬁcacy of different therapeutic schemes
using biologicals to treat patients with CD is
under discussion.
What are the new ﬁndings?
▸ Nucleotide-binding oligomerisation domain
containing 2 (NOD2) and ATG16L1 genetic
variants are independent risk factors for
bacterial DNA translocation in CD.
▸ Bacterial DNA translocation is directly
associated with disease activity and increases
the risk of relapse at 6 months.
▸ Patients with a NOD2 variant genotype showed
signiﬁcantly decreased phagocytic and
bactericidal activities, increased serum tumour
necrosis factor α (TNFα) levels in response to
bacterial DNA and signiﬁcantly decreased levels
of free serum anti-TNFα.
▸ In vitro Escherichia coli DNA-stimulated
neutrophils from patients with a NOD2 variant
genotype show lower serum levels of
anti-TNFα, suggesting faster drug consumption
How might it impact on clinical practice in
the foreseeable future?
▸ Our results identify a subgroup of patients with
an increased risk of bacterial DNA translocation
and, very likely, an increased risk of relapse.
▸ Classical anti-TNFα therapy regimens are likely
to decrease their efﬁcacy in controlling the risk
of ﬂare-up in these patients who might require
more aggressive therapeutic programmes to
reduce inﬂammation and episodes of bacterial
DNA translocation.
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antigens and in controlling intestinal immune responses to
luminal bacteria. Recently, we reported evidence of bacterial
DNA (bactDNA) translocation into the blood of patients with
CD. The associated innate immune response, which is partially
affected by nucleotide-binding oligomerisation domain contain-
ing 2 (NOD2) gene status,7 8 suggests a dysfunction in the epi-
thelial cell layer, an intestinal bacterial overgrowth or the
combination of both of these adverse events.
NOD2 encodes an intracellular receptor for the presence of
muramyl dipeptide (MDP), a common component of the bacterial
cell wall9–11 and has been identiﬁed as a prominent CD susceptibil-
ity gene.12 However, genome-wide association studies have
increased the number of genes that may potentially modulate CD
up to 71 loci.13 14 Among them, the autophagy gene, ATG16L1, is
very prominent.15–17 ATG16L1 is implicated in the modulation of
autophagy, an important cell survival mechanism also involved in
key aspects of the innate immune response to microorganisms.18
The CD-associated ATG16L1 variant, T300A, has been reported
to result in an autophagy defect,15 19 suggesting a role for autop-
hagy, and ATG16L1 in particular, in the pathogenesis of CD.
Recently, ATG16L1 and NOD2 have been reported to inter-
act in an autophagy-dependent antibacterial pathway in response
to MDP that is disrupted by speciﬁc CD-associated mutations.20
We have observed that patients with CD with a mutated NOD2
genotype cannot properly respond to bactDNA translocation.8
However, increasing evidence has been reported linking phago-
cytosis, a primary mechanism of host defence against bacterial
products, with the autophagy machinery.21 22 Therefore, we
hypothesise that the presence of bactDNA in the blood of
patients with CD may be associated with functional impairment
by the autophagy-related CD-associated gene mutation, further
complicating the disease outcome.
The aim of the present study was to determine whether the
presence of NOD2 and ATG16L1 mutations confer susceptibil-
ity to an impaired phagocytic activity and increased rates of
bactDNA translocation into the blood of patients with CD.
PATIENTS AND METHODS
Patients
A total of 179 consecutive patients with CD whose condition
was managed at the Inﬂammatory Bowel Disease (IBD) Unit of
the Hospital General Universitario de Alicante and who accepted
to participate in the study were included. The diagnosis of CD
was established according to standard clinical, endoscopic, histo-
logical and radiographical criteria.23 Patients who had received
antibiotics in the previous 2 weeks were not considered for inclu-
sion. All patients were classiﬁed according to the Montreal classi-
ﬁcation24 and stratiﬁed according to the Crohn’s Disease Activity
Index (CDAI). All included patients received diaries to record
symptoms 1 week prior to inclusion and sample collection.
Intensiﬁed therapy with biologicals was deﬁned either by an
increased dose or an increase in the frequency of infusions versus
dosing or schedule upon start of treatment. Twenty-ﬁve healthy
controls were also included in the study. All patients and controls
were Caucasian of Mediterranean ethnicity. Blood samples from
patients and healthy donors were obtained for routine haemato-
logical and biochemical studies and inoculated in aerobic and
anaerobic blood culture bottles, 10 ml each. Simultaneously, two
separate blood samples were inoculated under aseptic conditions
in rubber-sealed sterile Vacutainer SST II and K3E tubes, respec-
tively (BD Diagnostics, Erembodegem, Belgium) that were never
exposed to free air.
Patients were followed up for 6 months to evaluate the inci-
dence of relapse. Although ‘relapse’ strictly refers to the clinical
situation coming from remission, we wanted to evaluate
whether patients’ disease would turn into an active form in the
next 6 months after bactDNA detection, no matter their CDAI
status at admission. In the case of patients with a CDAI>150 at
admission, the ﬂare was controlled in all cases within the subse-
quent 2 weeks. The Ethics Committee of the hospital approved
the study protocol. All controls and patients gave informed
consent prior to inclusion in the study.
Identiﬁcation of bactDNA fragments and genotyping
of CD-associated genes
Genomic DNA was isolated from 5×106 cells with the QIAmp
DNA Blood Minikit (Qiagen, Hilden, Germany). BactDNA was
identiﬁed by running broad-range PCR followed by partial nucleo-
tide sequencing of a conserved region of the 16SrRNA gene, as
previously described.25 The three common NOD2/CARD15 allelic
variants at SNP-8 (R702W, rs2066844), SNP-12 (G908R,
rs2066845) and SNP-13 (L1007ﬁnsC, rs2066847) were evaluated
as previously described.26 The ATG16L1 variation rs2241880
(T300A) was genotyped by TaqMan technology (Applied
Biosystems, Carlsbad, California, USA) using commercially avail-
able TaqMan SNP Genotyping Assays and TaqMan Genotyping
Master Mix on a 7900HT Fast Real-Time PCR System using SDS
2.2 Software (Applied Biosystems). A variant NOD2 genotype
(varNOD2) was deﬁned as carrying any of the three variants
studied either in homozygosis or heterozygosis. A variant
ATG16L1 genotype (varATG16L1) was deﬁned as carrying the
rs2241880 variation either in homozygosis or heterozygosis. All
genotyping results were assessed twice. The evaluators were not
aware of either the patient’s disease status or each other’s genotype
results. A Hardy–Weinberg test was performed as a quality control
measure in controls. No missing genotypes were present.
Phagocytic and bactericidal assays
The phagocytic activity of neutrophils that ingest ﬂuorescein iso-
thiocyanate (FITC)-labelled opsonised Escherichia coli and the
bactericidal activity of neutrophils that oxidise the ﬂuorogenic
substrate dihydrorhodamine DHR123 to rhodamine R123 were
determined using the Phagotest and Bursttest Kits (Orpegen
Pharma, Heidelberg, Germany) following the manufacturer’s
instructions. Cells were quantiﬁed by ﬂow cytometry using a
FacsCanto (Becton Dickinson, Heidelberg, Germany) and the
data were processed using the FacsDiva 12.0 software (Becton
Dickinson).
Serum cytokine and free anti-TNFα levels: presence
of antidrug antibodies
ELISAs were carried out to measure tumour necrosis factor α
(TNFα), interferon γ (IFNγ), interleukin (IL)-12p40 (R&D
Systems, Minneapolis, Minnesota, USA), free inﬂiximab and
adalimumab levels and to detect antidrug antibodies (Matriks
Biotek, Ankara, Turkey) according to the manufacturers’ instruc-
tions. All samples were tested in triplicate and read in a Sunrise
Microplate Reader (Tecan, Männedorf, Switzerland). The detec-
tion limit for each cytokine assay varied between 2 and 5 pg/ml
and between 10 and 30 ng/ml in the case of free anti-TNFα kits.
The presence of antidrug antibodies was evaluated by a cut-off
value estimated by multiplying the optical density (OD) of the
zero standard by 3, as indicated by the manufacturers. Samples
were considered positive when the ratio sample OD/zero stand-
ard OD was higher than 3.
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Isolation and culture of human PMN cells
Polymorphonuclear leukocyte cells (PMNs) from peripheral
blood samples were isolated with PolymorphPrep (Axis-Shield
PoC, Oslo, Norway). After isolation of PMNs, cells were
washed twice with freshly made phosphate-buffered saline at
4°C. Cell viability was evaluated by trypan blue (Sigma, Madrid,
Spain). Cells were resuspended in phenol red-free RPMI 1640
medium (Gibco BRL, Life Technologies, Paisley, UK) supple-
mented with 10% human serum AB (BioWhittaker,
Walkersville, Maryland, USA). Neutrophils (1×106 cells/well)
were incubated with 200 ng of E coli DNA. Half of the super-
natant volumes were collected at 24 h and TNFα and annexin V
levels measured by ELISA. Cells were then treated with inﬂixi-
mab 100 μg/ml/106 cells (inﬂiximab was kindly provided by
Merck Sharp and Dohme of Spain MSD, Madrid, Spain).
Supernatants were collected at 48 h. Total endogenous annexin
V levels were evaluated as an indirect measurement of apoptotic
activity in neutrophils using a human Annexin V ELISA kit from
Promokine (Heidelberg, Germany), according to the manufac-
turer’s instructions.
Statistical analysis
Continuous variables are reported as the mean±SD and categor-
ical variables as frequency or percentages. The Kolmogorov–
Smirnov test was used to test normality of continuous variables.
Statistical differences were analysed using the χ2 test for categor-
ical data and analysis of variance (ANOVA) test for quantitative
data followed by the post hoc Bonferroni correction for mul-
tiple comparisons. Quantitative data showing non-normal distri-
bution were analysed using the Mann–Whitney U test or
Kruskal–Wallis test followed by pairwise comparisons using the
Mann–Whitney U test with the post hoc Bonferroni correction
for multiple comparisons. Bivariate correlations were analysed
using the Spearman test. Logistic regression analysis was used to
determine the association between NOD2/ATG16L1 genotypes
and bactDNA concentration or CDAI. We ﬁrst examined vari-
ables by univariate analysis, and then signiﬁcant factors at
p<0.10 were included in multivariate analysis. The results of
logistic regression are reported as OR and 95% CI. All reported
p values are two sided. p<0.05 values were considered signiﬁ-
cant. Analyses were performed using IBM SPSS Statistics 19.
RESULTS
Patient characteristics
The clinical and analytical characteristics of patients are detailed
in table 1, stratiﬁed according to the CDAI. No statistically sig-
niﬁcant differences were observed between groups regarding
age, gender, smoking habit or disease classiﬁcation by Montreal
criteria. Patients with active diease showed higher erythrocyte
sedimentation rate, C-reactive protein (CRP) and lower haemo-
globin and albumin levels than patients with remitting disease.
Steroid treatment was signiﬁcantly more frequent in patients
with active disease. Among healthy controls, the mean age was
32±11 years, the male/female ratio was 12 : 8 and 35% were
smokers. No differences in demographic and analytical para-
meters between controls and patients with remitting disease
were observed. All patients and controls included in the study
had negative blood microbiological cultures.
NOD2/ATG16L1 genotypes and bactDNA distribution
in patients with CD
The distribution of genotypes and allelic frequencies in patients
with CD and controls are shown in table 2. All variants were
found to be in the Hardy–Weinberg equilibrium in the controls.
Overall, 69% of patients with remitting disease and 76.4% of
patients with active disease showed at least one of the
Table 1 Patient characteristics
CDAI
<150 (n=136) >150 (n=43)
Age (years) 40±14 42±15
Weight (kg) 70.12±15.76 68.88±20.78
Gender (male/female) 65/71 18/24
Smoking habit, n (%) 48 (35%) 14 (32%)
Disease duration (months) 112.52±91.66 106.54±98.19
Resection, n (%) 36 (26%) 13 (30%)
Montreal A (age of onset), n (%)
A1 (<=16) 6 (4.4%) 3 (7%)
A2 (17–40) 107 (78,6%) 30 (69.7%)
A3 (>40) 23 (17%) 10 (23.3%)
Montreal L (location), n (%)
L1 (ileal) 70 (51.4%) 23 (53.4%)
L2 (colonic) 32 (23.5%) 5 (11.6%)
L3 (ileocolonic) 31 (22.8%) 12 (28%)
L4 (upper isolated) 3 (2.2%) 3 (7%)
Montreal B (behaviour), n(%)
B1 (non-stricturing, non-penetrating) 68 (50%) 19 (44.2%)
B1p (non-stricturing, non-penetrating,
penetrating perianal disease)
11 (8%) 2 (4.6%)
B2 (stricturing) 22 (16.3%) 13 (30.2%)
B2p (stricturing, perianal disease
associated)
7 (5.1%) –
B3 (penetrating) 24 (17.6%) 5 (13.6%)
B3p (penetrating, penetrating perianal
disease)
4 (2.9%) 4 (9.3%)
Therapy, n (%)
Mesalazine 35 (25.7%) 5 (11.6%) *
Steroids – 2 (4.6%)
Azathioprine 49 (36.0%) 4 (9.3%) *
Infliximab 7 (5.1%) 5 (11.6%)
Adalimumab 12 (8.8%) 2 (4.6%)
Metotrexate – 1 (2.4%)
Mesalazine and steroids 3 (2.2%) 5 (11.6%)
Mesalazine and azathioprine 7 (5.1%) 2 (4.6%)
Azathioprine and steroids 2 (1.4%) 10 (23.2%)*
Infliximab and azathioprine 8 (5.8%) 4 (9.3%)
Adalimumab and azathioprine 5 (3.6%) –
Infliximab and metotrexate 2 (1.4%) –
Infliximab and steroids 1 (0.7%) 2 (4.6%)
Adalimumab and steroids 3 (22%) –
Infliximab and azathioprine and steroids – 1 (2.3%)
No treatment 2 (1.4%) –
ESR (mm) 19.4±16.3 40.5±27.4*
CRP (mg/dl) 0.53±1.04 3.43±4.99*
Haemoglobin (g/dl) 13.93±3.02 12,49±1.66 *
Albumin (mg/d) 4073.05±453.02 3588.2
±573.47 *
Total WBCs (mm3) 6907.7±2757.24 7725.02
±2642.26
Temperature (°C) 36.09±0.26 36.54±0.58 *
Pulse rate (bpm) 70.17±5.43 72±7.47
All values shown as mean±SD or percentage.
CDAI, Crohn’s Disease Activity Index; CRP, C-reactive protein; ESR, erythrocyte
sedimentation rate; WBC, white blood cell.
*p<0.05 compared with CDAI <150.
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CD-associated gene variants. A NOD2 variant, either alone or
combined with the ATG16L1 variant, was present in 56
(41.2%) patients with remitting disease and in 18 (41.8%)
patients with active disease. The ATG16L1 variant, either alone
or combined with a NOD2 variant, was present in 82 (60.2%)
patients with remitting disease and in 24 (55.8%) patients with
active disease. Figure 1A shows the distribution of NOD2 and
ATG16L1 variants among patients with active CD and those
with remitting disease. The distribution of the genotypes under
study was not statistically signiﬁcant between groups (p=0.90).
From the overall series of patients, 51 of 179 (28.5%)
showed the presence of bactDNA in blood samples. By groups,
19 of 43 (44.2%) patients with clinically active disease and 32
of 136 (23.5%) patients with remitting disease showed
bactDNA (p=0.01). The identiﬁed bacterial species included
E coli (n=21), Staphylococcus aureus (n=12), Klebsiella pneu-
moniae (n=7), Streptococcus pneumoniae (n=5), Shigella spp.
(n=3), Enterococcus faecalis (n=2) and Campylobacter freundii
(n=1). No statistical differences in bacterial species were
observed between the studied genotypes. BactDNA was absent
in the blood of healthy controls. A univariate analysis revealed
that the presence of bactDNA in the blood, among others, was
signiﬁcantly associated with disease activity with an OR of 2.6
(95% CI 1.3 to 5.4; p=0.005) whereas single and double-gene
mutations were not directly associated with disease activity
(p=0.19). As expected, the use of steroids and inﬂiximab was
also signiﬁcantly associated with disease activity, as they are a
usual therapeutic ﬁrst approach on a ﬂare-up (see online supple-
mentary table S1). A multivariate analysis including variables
showing a p value<0.1 on the univariate analysis is detailed in
table 3. Of note, bactDNA remained signiﬁcantly and independ-
ently related to disease activity.
BactDNA was present in 5 of 47 (10.6%) patients with
wtNOD2/wtATG16L1, 8 of 26 (30.7%) with varNOD2/
wtATG16L1, 9 of 57 (15.5%) with wtNOD2/varATG16L1 and
29 of 48 (60.4%) with varNOD2/varATG16L1. Figure 1B dis-
plays the percentage of bactDNA presence in each studied geno-
type, distributed by CDAI. The percentage of patients with
bactDNA was signiﬁcantly increased in the varNOD2 genotype
groups. Unlike the double wild-type genotype, single NOD2 or
ATG16L1 variants were signiﬁcantly associated with the pres-
ence of bactDNA on the univariate analysis (OR 4.8; 95% CI
1.1 to 13.3; p=0.03; and OR 2.4; 95% CI 1.46 to 4.5;
p=0.05, respectively). This effect was more pronounced in
patients with a double-variant genotype (OR 12.7; 95% CI 4.2
to 37.8; p=0.001) (see online supplementary table S2). All
studied gene variants and disease activity remained signiﬁcantly
and independently associated with bactDNA presence on the
multivariate analysis (table 3).
No differences among the three examined NOD2 allelic var-
iants were observed for CDAI or any other clinical characteris-
tics of patients with varNOD2. No statistically signiﬁcant
differences were observed, either between patients stratiﬁed by
genotype or by presence of bactDNA, although CRP, total white
blood cell count and CDAI were higher in patients with
bactDNA (data not shown).
In 43 patients disease relapsed during this period (24%): 20
of 51 (40%) patients with bactDNA at inclusion versus 23 of
128 (18%) patients without bactDNA (p=0.01). BactDNA in
the blood, among other things, was signiﬁcantly associated with
an increased risk of ﬂare-up at 6 months on the initial univariate
analysis, with an OR of 3.32 (95% CI 1.5 to 7.3; p=0.003)
Figure 1 (A) Distribution of NOD2/ATG16L1 combined genotypes in
patients with Crohn’s disease stratiﬁed by CDAI. (B) Percentage of
bactDNA presence in each studied genotype distributed by CDAI;
*p<0.01 compared with the wtNOD2/wtATG16L1 genotype group.
bactDNA, bacterial DNA; CDAI, Crohn’s Disease Activity Index; NOD2,
nucleotide-binding oligomerisation domain containing 2; var, variant;
wt, wild type.
Table 2 Distribution of genotypes and allelic frequencies in patients with Crohn’s disease and controls
Gentotype (n (%) patients/controls)
Variant allele frequency (%)Homozygous wild type Heterozygous Homozygous variant
NOD2 SNP8 (R702W) 136 (76%)/24 (96%) 43 (24%)/1 (4%) 0/0 12.0/2.0
NOD2 SNP12 (G908R) 152 (85%)/24 (96%) 26 (14.5%)/1 (4%) 1 (0.5%)/0 7.8/2.0
NOD2 SNP13 (L1007finsC) 164 (92%)/24 (96%) 15 (8.4%)/1 (4%) 0/0 4.7/2.0
ATG16L1 (T300A) 73 (41%)/22 (88%) 84 (47%)/5 (20%) 22 (12.3%)/0 35.8/10.0
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(see online supplementary table S3). The multivariate analysis
revealed bactDNA presence as the only independent factor asso-
ciated with relapse at 6 months (table 3). Thirty-three patients
(18.4%) received short-term courses of oral antibiotics during
the 6-month follow-up period due to non-CD-related causes
with no statistically signiﬁcant effect on the risk for relapse
among patients, either stratiﬁed by genotype or by the presence
of bactDNA at admission. There was no statistical association
between bactDNA presence at admission and the subsequent
need for antibiotics, complications such as surgery or readmis-
sions during the follow-up period among the different genotype
subgroups.
Immunological activity in response to bactDNA in patients
with different NOD2/ATG16L1 genotypes
We evaluated the proinﬂammatory cytokine response to the
presence of bactDNA in the serum of patients with CD, strati-
ﬁed by genotype. The results are shown in table 4. No differ-
ences were observed between patient groups without bactDNA.
The proinﬂammatory activity was signiﬁcantly increased in
patients with bactDNA compared with that observed in patients
without bactDNA, irrespective of genotype. However, patients
with bactDNA and a variant NOD2 genotype, either alone or
combined with a variant ATG16L1 genotype, showed a further
statistically signiﬁcant increase compared with wild-type NOD2
genotype subgroups. Furthermore, the highest proinﬂammatory
levels were obtained in serum from patients carrying a combined
NOD2/ATG16L1 double-variant genotype. An ANOVA analysis
of proinﬂammatory cytokines including different variables and
their combinations revealed that bactDNA and the interaction
between bactDNA and genotype were the only statistically sig-
niﬁcant variables (data not shown).
Phagocytic and bactericidal activities were evaluated in blood
neutrophils treated with a ﬂuorochrome-labelled E coli from
the ﬁrst 12 patients with remitting disease without bactDNA of
each genotype-stratiﬁed subgroup (n=48). As shown in ﬁgure 2,
phagocytic and bactericidal activities were signiﬁcantly
decreased in the neutrophils of patients with varNOD2/
wtATG16L1 and varNOD2/varATG16L1 genotypes, with no
differences between these two groups. To investigate whether
these results were affected by ongoing treatment, phagocytic
and bactericidal activities were also evaluated in healthy controls
without bactDNA carrying NOD2 (n=3) and ATG16L1 (n=5)
variants or wild-type variants (n=10). As in patients, these
Table 4 Serum cytokine levels in patients with different NOD2/ATG16L1-combined genotypes according to the presence of bacterial DNA
TNFα (pg/ml) IFN-γ (pg/ml) IL-12 (pg/ml)
Bacterial DNA– (n=128)
wtNOD2/wtATG16L1 (n=43) 28.08±6.89 30.21±4.06 54.19±7.70
varNOD2/wtATG16L1 (n=18) 28.71±4.91 31.81±4.37 52.31±6.45
wtNOD2/varATG16L1 (n=48) 30.09±4.50 34.78±7.64 52.64±5.71
varNOD2/varATG16L1 (n=19) 3012±3.48 32.04±5.70 50.72±5.20
wtNOD2/wtATG16L1 (n=5) 49.57±6.92* 59.32±6.1* 91.16±11.8*
Bacterial DNA+ (n=51)
varNOD2/wtATG16L1 (n=8) 75.67±7.80* ** 82.86±7.48* ** 124.01±15.5* **
wtNOD2/varATG16L1 (n=9) 50.70±8.73* 61.43±6.6* 98.73±12.43*
varNOD2/varATG16L1 (n=29) 79.50±8.93* ** 85.60±8.27* ** 138.49±17.5* **
*p<0.01 compared with same genotype in patients who are bacterial DNA negative.
**p<0.01 compared with the wtNOD2 genotypes in patients who are bacterial DNA positive.
IFN, interferon; IL, interleukin; TNFα, tumour necrosis factor α.
Table 3 Multivariate analyses of disease activity, bacterial DNA and relapse at 6 months, including variables with a p value <0.1 on univariate
analysis
Multivariate analysis
Variable p Value OR 95% CI
Dependent variable: disease activity (CDAI<150/CDAI>150)
Presence of bacterial DNA fragments (yes/no) 0.008 7.422 1.690 to 32.596
Steroid treatment (yes/no) 0.001 27.303 4233 to 176116
Infliximab treatment (yes/no) 0.001 16.649 3.213 to 86.288
C-reactive protein (mg/dl) 0.001 3.833 1.679 to 8.752
Dependent variable: bacterial DNA
Disease activity (CDAI>150/CDAI<150) 0.001 5.084 1.972 to 13.106
Genotype
wtNOD2/wtATG16L1 0.000
varNOD2/wtATG16L1 0.020 5.117 1.287 to 20.346
wtNOD2/varATG16L1 0.0401 2.221 1.394 to 5.118
varNOD2/varATG16L1 0.000 12.728 3.738 to 43.344
Dependent variable: relapse at 6 months (yes/no)
Presence of bacterial DNA fragments (yes/no) 0.003 5.132 1.764 to 14.926
CDAI, Crohn’s Disease Activity Index.
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activities were decreased in healthy donors carrying any NOD2
variant compared with ATG16L1 variant and wild-type geno-
types (data not shown).
Intensiﬁed anti-TNFα therapy is more frequent in patients
with mutated NOD2/ATG16L1-combined genotypes
Next, we evaluated whether these combined genotypes had an
impact on anti-TNFα therapy schedules. Fifty-two of the 179
patients (29%) were on anti-TNFα therapy at inclusion, either
combined with immunosuppressive treatment or not, 30 on
inﬂiximab and 22 on adalimumab (see table 1). Figure 3A,B
show the percentage of patients on anti-TNFα therapy and, of
those, the percentage of patients on an intensiﬁed schedule of
anti-TNFα therapy, either stratiﬁed by genotype or by the pres-
ence of bactDNA. As detailed, the proportion of patients on
intensiﬁed therapy was higher in the groups with either a
varNOD2/wtATG16L1 or a varNOD2/varATG16L1 genotype.
No statistically signiﬁcant differences were observed in the per-
centage of smokers, the time from diagnosis or the time from
initiation of anti-TNFα therapy between patients on intensiﬁed
treatment and those on non-intensiﬁed treatment, all of which
could affect the need for intensiﬁcation (see online supplemen-
tary table S4). Twenty percent of patients receiving anti-TNFα
therapy showed bactDNA in blood, of which 50% were on an
intensiﬁed drug schedule. By contrast, only 33% of patients
without bactDNA received intensiﬁed treatment (p=ns). No dif-
ferences were observed for the distribution of each anti-TNFα
among patients, either grouped by genotype or by the presence
of bactDNA.
Free anti-TNFα levels were measured in the serum of patients
receiving therapy with biologicals and stratiﬁed according to
their genotype and the presence of bactDNA. The results were
restricted to samples that were negative for the presence of anti-
drug antibodies (n=48) and are shown in ﬁgure 3C.
Signiﬁcantly decreased levels of free anti-TNFα were observed
in the varNOD2/wtATG16L1 and varNOD2/varATG16L1
genotype-based subgroups, despite showing a signiﬁcant number
of patients on an intensiﬁed schedule. The presence of bactDNA
further decreased the levels of free serum anti-TNFα, although
the number of individuals was too small to report statistics.
Figure 3 (A) Percentage of patients on intensiﬁed anti-tumour necrosis factor α (TNFα) therapy stratiﬁed according to NOD2/ATG16L1-combined
genotypes. (B) Percentage of patients on intensiﬁed anti-TNFα therapy according to the presence of bactDNA. (C) Free anti-TNFα levels in serum of
patients receiving therapy with biologicals, either alone or combined with immunosuppressive treatment, stratiﬁed according to each genotype
studied and to the presence of bactDNA; *p<0.01 compared with wtNOD2 groups. (D) Free anti-TNFα levels in serum of patients on monotherapy
with biologicals, stratiﬁed according to each genotype studied and to the presence of bactDNA; *p<0.01 compared with wtNOD2 groups. bactDNA,
bacterial DNA; NOD2, nucleotide-binding oligomerisation domain containing 2; var, variant; wt, wild type.
Figure 2 Phagocytic (A) and
bactericidal (B) activities in neutrophils
of patients with NOD2/ATG16L1
combined genotypes (n=12/each
group) without bactDNA translocation
into blood; *p<0.01 compared with
wtNOD2 groups. bactDNA, bacterial
DNA; NOD2, nucleotide-binding
oligomerisation domain containing 2;
MF, mean ﬂuorescence; wt, wild type.
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Since interactions between biologicals and azathioprine or
methotrexate have been described, we repeated the analysis
excluding patients on combined therapies in samples with an
absence of serum antidrug antibodies (n=24) obtaining compar-
able results (ﬁgure 3D).
As stated above, 3 of 30 (10%) patients on inﬂiximab and 1 of
22 (4.5%) on adalimumab showed the presence of antidrug
antibodies (see methods) and were excluded from the analyses pre-
sented in ﬁgure 3C,D. None of these patients showed the presence
of bactDNA in the blood. Two patients had a wtNOD2/
wtATG16L1 genotype and were on combined therapy. One patient
had a wtNOD2/wtATG16L1 genotype and was on monotherapy
with inﬂiximab. One patient had a wtNOD2/varATG16L1 geno-
type and was on monotherapy with adalimumab.
Free anti-TNFα levels are decreased in the supernatants of
neutrophils from patients with variant NOD2/ATG16L1
exposed to bactDNA
We designed an in vitro experiment with neutrophils isolated
immediately before anti-TNFα infusion (trough levels) from the
same 12-patient genotype-stratiﬁed subgroups without
bactDNA, excluding those who showed the presence of antidrug
antibodies. The results are shown in ﬁgure 4.
Levels of TNFα were signiﬁcantly increased after 24 h E coli
bactDNA stimulation in the subgroups bearing a variant versus
wild-type NOD2 genotype (ﬁgure 4A). Baseline and 24 h
unstimulated supernatant levels are also represented. No differ-
ences in the apoptotic activity of neutrophils at this time point
were observed among groups (ﬁgure 4B). Forty-eight hours
after anti-TNFα addition, levels of TNFα were signiﬁcantly
decreased in all subgroups with wild-type NOD2. This reduc-
tion was not observed in the supernatants of cells with a NOD2
variant. However, a signiﬁcant reduction in free anti-TNFα
levels was found in the supernatants of the subgroups carrying a
variant NOD2 genotype, either alone or combined, compared
with wild-type NOD2 (ﬁgure 4C). No differences in apoptotic
activity of neutrophils between groups were observed at this
time point (ﬁgure 4D).
DISCUSSION
Patients with a NOD2-variant genotype, either alone or com-
bined with an ATG16L1-variant genotype, show an increase in
secreted TNFα levels in response to bactDNA translocation and,
therefore, a faster consumption of free anti-TNFα. This ﬁnding
could be clinically important since these patients may require
intensiﬁed anti-TNFα therapy, have an increased risk of
bactDNA translocation, and have an increased risk of relapse.
The number of IBD-associated susceptibility genes has
increased in recent years to over 100.16 27 Among them,
autophagy-related genes, especially ATG16L1, have emerged as
new key players15 17 along with others that were previously
identiﬁed, such as NOD2, classically associated with the devel-
opment of CD.26 Although the association between NOD2 var-
iants and the increased risk of complicated CD has been
reported in the past,28–30 none of these genes has been linked
so far with the risk of disease ﬂare-ups. We report here that
Figure 4 (A) Tumour necrosis factor α (TNFα) levels in the supernatants of neutrophils from patients with different NOD2/ATG16L1 genotypes
exposed to Escherichia coli DNA; $p<0.01 compared with baseline and unstimulated conditions; *p<0.01 compared with wtNOD2 groups.
(B) Apoptotic activity of 24 h cultured neutrophils from patients of each genotype subgroup. (C) Free anti-TNFα levels in the supernatants of
neutrophils from patients with studied NOD2/ATG16L1 genotypes exposed to E coli DNA and treated with inﬂiximab; *p<0.01 compared with
wtNOD2 groups. (D) Apoptotic activity of 72 h cultured neutrophils from patients of each genotype subgroup. NOD2, nucleotide-binding
oligomerisation domain containing 2; var, variant; wt, wild type.
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bactDNA translocation is signiﬁcantly associated with the
disease activity and the presence of NOD2/ATG16L1 gene var-
iants, suggesting that bactDNA translocation might be facilitated
in patients with variant NOD2/ATG16L1-combined genotypes,
increasing the risk of ﬂare-up in these patients (ﬁgure 1). In fact,
genetic interactions between polymorphisms in toll-like receptor
9, the speciﬁc receptor for immunogenic CpG motifs present in
bactDNA, and CD-associated variants in NOD2 and other
genes have been previously described.31
In our study, patients bearing a NOD2 gene variant, either
alone or combined with a variant ATG16L1 genotype, showed
signiﬁcantly reduced phagocytic and bactericidal activity (ﬁgure
2). NOD2 genetic alterations have also been associated with a
defective innate response in the past.32 Interestingly, our data
indicate that NOD2 may be involved in the phagocytic and bac-
tericidal capacities of blood neutrophils, facilitating its ability to
clear bacteria and their components from the blood of these
patients. We hypothesised that the persistence of bactDNA frag-
ments in the blood of patients with NOD2 mutation would cor-
relate with an increased proinﬂammatory cytokine response.
Accordingly, data shown in table 4 revealed that NOD2-mutated
genotypes were associated with higher levels of these cytokines.
The role of TNFα in the pathogenesis of CD is clearly evi-
denced by the efﬁcacy of anti-TNFα therapies.33–36 However,
our understanding of the effect of different NOD2/ATG16L1
genotypes and bactDNA presence on these therapies is not
complete. The proportion of patients on intensiﬁed treatment
was signiﬁcantly higher in patients with a variant NOD2/
ATG16L1-combined genotype. At the same time, free
anti-TNFα levels were signiﬁcantly decreased in the serum of
patients with any of the NOD2 variants and especially in those
with a combined NOD2/ATG16L1-variant genotype. These
data are clinically relevant since low serum anti-TNFα levels
have been associated with a deﬁcient response, and therapeutic
drug monitoring has been recommended in the clinical manage-
ment of patients with CD.37–39 Inter-individual variability has
been a constant ﬂaw in studies reporting pharmacokinetic data
on anti-TNFα levels so far. The use of concomitant drugs such
as azathioprine or methotrexate has also been reported to inﬂu-
ence clearance of anti-TNFα and the development of immuno-
genicity.40 41 To address this question, we analysed the free
anti-TNFα levels in patients receiving anti-TNFα monotherapy,
obtaining comparable results but with reduced variability. These
results suggest that combined therapies, NOD2/ATG16L1 geno-
types and the presence of bactDNA may account for the high
variability observed in serum-free anti-TNFα levels and might
provide an explanation for the need for intensiﬁed anti-TNFα
therapy. One may think of the intensiﬁed biological schedule as
the cause for the increased bacterial translocation and the subse-
quent bactDNA detection in the varNOD2 group. However,
only 20% of patients on anti-TNFα therapy have bactDNA and,
of those, 50% received intensiﬁed treatment. This percentage
was not signiﬁcantly different from the 33% of patients without
bactDNA who were on drug intensiﬁcation. Besides, if that were
the case, lower bactDNA rates might be expected in patients
with varNOD2 not receiving biological therapy versus those on
biological therapy but bactDNA is present in 52.7% of patients
with varNOD2 receiving anti-TNFα therapy versus 29.4% of
those not receiving anti-TNF-α therapy (p=ns).
These results are further supported by our in vitro studies, in
which neutrophils from patients with NOD2 and ATG16L1 var-
iants showed an accelerated drug consumption rate (ﬁgure 4).
Although the highest TNFα levels were observed in samples
from mutated genotypes treated with E coli DNA and despite
the fact that 24 h unstimulated cells did not show an increase in
TNFα compared with baseline, the possibility of an inﬂamma-
tory peak, earlier to or independent of biological therapy, is not
completely ruled out. Nevertheless, these results point to the
identiﬁcation of a subgroup of patients with CD with the poten-
tial need for a more aggressive therapeutic approach to efﬁ-
ciently control their disease course or, at least, in which the
current therapies are not as effective as in patients with a wild-
type NOD2 genotype. Some studies have evaluated ‘top-down’
versus ‘step-up’ therapies and these strategies are presently
under discussion.42 43 In our series the presence of bactDNA
was signiﬁcantly associated with relapse in the 6-month
follow-up period. Although evaluating risk factors for relapse
was not the aim of this study, the preliminary data reported here
support the design and development of new studies, including
multivariate analysis of known risk factors for the clinical
course of the disease, such as the lack of mucosal healing,44 the
use of non-steroidal anti-inﬂammatory drugs,45–47 treatment
withdrawal48 49 and others.
In summary, combined NOD2/ATG16L1 variant genotypes
identify a patient subgroup with an increased risk of bactDNA
translocation. This fact may, in turn, exacerbate the inﬂamma-
tory response and is directly associated with disease activity and
the risk of relapse in the short term. This persistent inﬂamma-
tory environment would favour the requirement for therapy
intensiﬁcation in patients with mutation on treatment with bio-
logicals, who would probably be candidates for a different
therapeutic strategy.
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